|
|
|
| home > pmps > autumn 2003 > the impact of the eu clinical trials directive on the supply chain |
|
|
 PUBLICATIONS |
Pharmaceutical Manufacturing and Packing Sourcer
|
The European Union is about to enter a new era in the conduct of clinical trials within its jurisdiction. The vastly different range of current approaches from member states to trials are going to converge on 1st May 2004. At least that is the intention. Will we make it on time or will national differences on interpretation make it impossible? Not only that, but how will the new accession countries intending to join the EU in May 2004 fare? In both cases, only time will tell.
This article broadly highlights certain aspects of the changes to clinical supplies as demanded by the Directive (1) and encouraged by the accompanying publication of guidance in the revised Annex 13 (2) to European Good Manufacturing Practice (GMP). Readers may find that these changes already exist in many Member States' legislation, but in most countries the requirements are new.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
3P Biopharmaceuticals and Nordic Nanovector have extended partnership for Betalutin® late stage manufacturing for B-cell non-Hodgkin lymphoma (NHL) treatment
The non-Hodgkin lymphoma (NHL) is a cancer that starts in white blood cells called lymphocytes, which are part of the body’s immune system
More info >> |
|
 |
White Papers |
 |
|
Driving ROI: The Case for Investing in Contract & Site Regulatory Document Management Services
DrugDev
With tight timelines and complicated regulatory documentation requirements, getting a clinical trial up and running quickly is easier said than done. Key milestones can be achieved only after the successful negotiation of clinical trial agreements and completion of essential regulatory documents. Many clinical trials are hindered by inefficient, labor-intensive processes. Prolonged, inefficient activation can hamper investigator satisfaction and, ultimately, have a negative bottom-line impact for sponsors and CROs. In addition, the Sunshine Act is heightening the importance of financial disclosure in clinical trials. Without a robust financial disclosure strategy, sponsors cannot ensure that physician self-reported financial disclosure data are aligned with the payment data being reported through the Sunshine Act, increasing financial and regulatory risk.
More info >> |
|
 |
Industry Events |
 |
Nordic Life Science Days 10/12 September 2019
10-12 September 2019, Malmo Sweden
Nordic Life Science Days is the largest Nordic partnering conference for the global Life
Science industry.
Bringing together the best talents in Life Science, offering amazing networking and
partnering opportunities, providing inputs and content on the most recent trends.
Nordic Life Science Days attracts leading decision makers from the Life Science sector,
not only from biotech, pharma and medtech but also from finances, research, policy and
regulatory authorities.
More info >> |
|
|
